Date: Thursday, April 3rd, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia A or B with inhibitors OBJECTIVE: To provide a prescribing information overview of the recently FDA approved medication, Alhemo (concizumab-mtci), for patients living with hemophilia A or B with Read the full article...

Date: Tuesday, May 6th, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Complications and challenges associated with hemophilia and a rebalancing approach with HYMPAVZI™ (marstacimab-hncq) OBJECTIVES: Educate attendees on complications and challenges associated with hemophilia, the novel mechanism of action of HYMPAVZI, the BASIS Ph3 clinical trial results and dosage and Read the full article...

Date: Wednesday, May 7th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: Exploring data and expert perspectives on Qfitlia™ (fitusiran) OBJECTIVE: During this program, we will explore data and expert perspectives on Qfitlia™ (fitusiran), a newly approved prophylactic treatment for patients with hemophilia A and B, with or without inhibitors. SPEAKER: Vanessa Read the full article...

Date: Tuesday, May 13th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: A Collaborative Journey - ROCTAVIAN Patient & Provider Perspectives OBJECTIVE: Join us for an insightful webinar exploring the real-world experiences of patients and providers with ROCTAVIAN. Hear firsthand accounts of the treatment journey, from initial consultations and administration to outcomes Read the full article...

Date: Wednesday, August 27th, 2025 Time: 2:00pm - 3:00pm ET           WEBINAR TITLE: Juggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. OBJECTIVES: To educate attendees on challenges, shared decision making in hemophilia and introduce Read the full article...

Date: Thursday, September 4th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TITLE: Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence, Patient Perspective & Contract Opportunities. OBJECTIVES: Explore updates to HEM Alliance member contract terms and the associated provider economics. Review the latest clinical data updates, describing the long-term efficacy and safety of Read the full article...

Date: Wednesday, September 10th, 2025 Time: 1:00pm - 2:00pm ET         WEBINAR TITLE: Mental Health and Substance Use in the Bleeding Disorders Community. DESCRIPTION: The bleeding disorders community does not have the same access to inpatient and residential mental health and substance use treatment that the general population does. This webinar will Read the full article...

Date: Wednesday, September 17th, 2025 Time: 2:00pm - 3:00pm ET       WEBINAR TOPIC: Qfitlia Overview: Clinical, Access, and Distribution Dynamics. OBJECTIVE: Dr. Lynn Malec will review key elements of the Qfitlia efficacy and safety profile and Adam Gurry, Sanofi Director of Access Strategy, will provide insights on the Qfitlia access and distribution strategy. Read the full article...

Date: Wednesday, October 1st, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: On-demand and Surgical Use of ADVATE® OBJECTIVE: This session will explore critical aspects of hemophilia A management, focusing on the unique role of ADVATE in on-demand and perioperative settings. AUDIENCE: All HTC Staff. SPEAKER: Jessica Grandoni, Pharm.D., BCPS, was the Read the full article...

Date: Wednesday, October 15th, 2025 Time: 2:00pm - 3:00pm ET     WEBINAR TOPIC: Prophylaxis in VWD: Iron as a Metric of Success at Healing. WEBINAR SUMMARY: A presentation on rethinking prophylaxis in VWD through a lens of healing and iron status. This presentation explores a multidimensional approach to bleeding disorders, with a focus on Read the full article...

Date: Thursday, October 23rd, 2025 Time: 3:00pm - 4:00pm ET       WEBINAR TITLE: Revolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A. DESCRIPTION: Please join us for an engaging discussion featuring nurses Jennifer Maahs, RN, PNP, MSN and Joseph Stanco, MSN, DNP, CCRC as they share Read the full article...

Date: Thursday, October 30th, 2025 Time: 2:00pm - 3:00pm ET       WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia. OBJECTIVE: To provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors, and supporting data from the explorer8 trial. AUDIENCE: Read the full article...

Date: Thursday, November 6th, 2025 Time: 1:00pm - 2:00pm ET           WEBINAR TOPIC: Jivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years. OBJECTIVE: This session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data Read the full article...

Date: Wednesday, November 12th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: VONVENDI® Approved for Adults and Pediatric Patients. OBJECTIVE: Understand the underlying mechanism of VWD and the role of VWF. Review unmet needs in the treatment of VWD. Identify the unique characteristics of VONVENDI as the first and only recombinant treatment Read the full article...

Date: Thursday, November 13th, 2025 Time: 1:00pm - 2:00pm ET         WEBINAR TOPIC: The HEMGENIX Toolkit OBJECTIVE: Overview of the tools and resources available to treatment centers to help support patients eligible and interested in HEMGENIX AUDIENCE: All HTC Staff. SPEAKER: Bonnie Ben-Shmuel Bonnie Ben-Shmuel is a seasoned biopharmaceutical marketing leader with Read the full article...

Date: Wednesday, December 3rd, 2025 Time: 2:00pm - 3:00pm ET       WEBINAR TOPIC: Translating Evidence into Practice: ​Real-World Patient Cases with ALTUVIIIO. OBJECTIVE: This session will bring together clinical evidence and real-world experience to illustrate how ALTUVIIIO can optimize treatment and improve outcomes for patients living with Hemophilia A. AUDIENCE: All HTC Staff. Read the full article...

Date: Thursday, December 11th, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TITLE: New! Real-World Evidence to Support Optimization of Factor IX Prophylaxis SUMMARY: This webinar will discuss recent evidence on prophylactic treatment strategies for hemophilia B from a U.S. real-world retrospective analysis of factor IX products. The session will highlight factor Read the full article...

Date: Thursday, January 15th, 2026 Time: 1:00pm - 2:00pm ET         WEBINAR TITLE: Five-Year Analysis: Efficacy and Safety of HEMGENIX® SUMMARY: Presentation of the published efficacy and safety results of the five-year analysis of the HOPE-B clinical trial follow up. AUDIENCE: All HTC Staff. SPEAKER: Vidhi Desai, Senior Medical Director (Coagulation), US Read the full article...